Shuqing Chen - Search Results

Year	Number of Results
2002	1
2003	1
2004	2
2005	2
2006	4
2007	6
2008	9
2009	11
2010	4
2011	6
2012	6
2013	27
2014	13
2015	17
2016	11
2017	21
2018	21
2019	31
2020	23
2021	27
2022	14
2023	16
2024	7

1

Emerging new therapeutic antibody derivatives for cancer treatment.

Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S, Pan L. Jin S, et al. Among authors: chen s. Signal Transduct Target Ther. 2022 Feb 7;7(1):39. doi: 10.1038/s41392-021-00868-x. Signal Transduct Target Ther. 2022. PMID: 35132063 Free PMC article. Review.

2

Palladium(II)-Initiated Catellani-Type Reactions.

Cheng HG, Chen S, Chen R, Zhou Q. Cheng HG, et al. Among authors: chen s. Angew Chem Int Ed Engl. 2019 Apr 23;58(18):5832-5844. doi: 10.1002/anie.201813491. Epub 2019 Feb 20. Angew Chem Int Ed Engl. 2019. PMID: 30589184 Review.

3

STING licensing of type I dendritic cells potentiates antitumor immunity.

Wang J, Li S, Wang M, Wang X, Chen S, Sun Z, Ren X, Huang G, Sumer BD, Yan N, Fu YX, Gao J. Wang J, et al. Among authors: chen s. Sci Immunol. 2024 Feb 16;9(92):eadj3945. doi: 10.1126/sciimmunol.adj3945. Epub 2024 Feb 16. Sci Immunol. 2024. PMID: 38363830

4

Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.

Zhao W, Wu J, Chen S, Zhou Z. Zhao W, et al. Among authors: chen s. Pharmacogenomics. 2020 Jun;21(9):637-645. doi: 10.2217/pgs-2019-0184. Epub 2020 May 19. Pharmacogenomics. 2020. PMID: 32423288 Review.

5

Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors.

An L, Wang Y, Wu G, Wang Z, Shi Z, Liu C, Wang C, Yi M, Niu C, Duan S, Li X, Tang W, Wu K, Chen S, Xu H. An L, et al. Among authors: chen s. Transl Res. 2023 May;255:14-25. doi: 10.1016/j.trsl.2022.11.002. Epub 2022 Nov 5. Transl Res. 2023. PMID: 36347492 Free article.

6

Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.

Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J. Kalim M, et al. Among authors: chen s. Drug Des Devel Ther. 2017 Aug 2;11:2265-2276. doi: 10.2147/DDDT.S135571. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28814834 Free PMC article. Review.

7

T52 attenuates oncogenic STAT3 signaling and suppresses osteosarcoma.

Tian L, Li C, Xiang L, Zeng J, Chen S, Guo W, Chen S, Wang Y, He X, Su P, Xu C. Tian L, et al. Among authors: chen s. Phytomedicine. 2023 Jun;114:154799. doi: 10.1016/j.phymed.2023.154799. Epub 2023 Apr 3. Phytomedicine. 2023. PMID: 37058945 Free article.

8

Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein.

Gao ZZ, Li C, Chen G, Yuan JJ, Zhou YQ, Jiao JY, Nie L, Qi J, Yang Y, Chen SQ, Wang HB. Gao ZZ, et al. Protein Expr Purif. 2022 Jan;189:105973. doi: 10.1016/j.pep.2021.105973. Epub 2021 Sep 22. Protein Expr Purif. 2022. PMID: 34560256 Review.

9

Functions of thymic stromal lymphopoietin in non-allergic diseases.

Ying G, Zhang Y, Tang G, Chen S. Ying G, et al. Among authors: chen s. Cell Immunol. 2015 Jun;295(2):144-9. doi: 10.1016/j.cellimm.2015.03.006. Epub 2015 Mar 23. Cell Immunol. 2015. PMID: 25880106 Review.

10

Effects of coffee on type 2 diabetes mellitus.

Akash MS, Rehman K, Chen S. Akash MS, et al. Among authors: chen s. Nutrition. 2014 Jul-Aug;30(7-8):755-63. doi: 10.1016/j.nut.2013.11.020. Epub 2013 Dec 5. Nutrition. 2014. PMID: 24984989 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

247 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Results by year